• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Pseudomonas Infections - Pipeline Review, H2 2012 Product Image

Pseudomonas Infections - Pipeline Review, H2 2012

  • ID: 2366404
  • December 2012
  • 157 pages
  • Global Markets Direct

Pseudomonas Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pseudomonas Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pseudomonas Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pseudomonas Infections. Pseudomonas Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pseudomonas Infections.
- A review of the Pseudomonas Infections products under development by companies READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Pseudomonas Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Pseudomonas Infections 9
Pseudomonas Infections Therapeutics under Development by Companies 11
Pseudomonas Infections Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Pseudomonas Infections Therapeutics – Products under Development by Companies 20
Pseudomonas Infections Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Pseudomonas Infections Therapeutics Development 25
Aradigm Corporation 25
Sanofi-Aventis 26
Targeted Genetics Corporation 27
Merck & Co., Inc. 28
Symphogen A/S 29
Rib-X Pharmaceuticals, Inc. 30
Novartis AG 31
Bayer AG 32
PARI Pharma GmbH 33
Insmed Incorporated 34
Intercell AG 35
Basilea Pharmaceutica Ltd. 36
Achaogen Inc. 37
Evolva SA 38
Novexel SA 39
Aridis Pharmaceuticals LLC 40
Mondobiotech Holding AG 41
Kenta Biotech Ltd. 42
Polyphor Ltd. 43
Microbiotix, Inc. 44
NanoBio Corporation 45
Ancora Pharmaceuticals Inc. 46
Tetraphase Pharmaceuticals Inc. 47
GlycoMimetics, Inc. 48
Phico Therapeutics Ltd. 49
SelectX Pharmaceuticals, Inc. 50
PepTx, Inc. 51
Trana Discovery, Inc. 52
Cantab Biopharmaceuticals Limited 53
Pseudomonas Infections – Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
ciprofloxacin - Drug Profile 60
amikacin - Drug Profile 62
amikacin - Drug Profile 64
ACHN-975 - Drug Profile 66
ciprofloxacin - Drug Profile 67
Sym-006 - Drug Profile 69
POL-7080 - Drug Profile 70
panobacumab - Drug Profile 71
RX-04 - Drug Profile 73
KBPA-104 - Drug Profile 74
KBPA-103 - Drug Profile 75
KBPA-102 - Drug Profile 76
NXL-105 - Drug Profile 77
tobramycin - Drug Profile 78
GMI-1051 - Drug Profile 80
IC-43 - Drug Profile 81
Aerucin - Drug Profile 82
Expanded-Spectrum Aminoglycosides Development Program - Drug Profile 83
tobramycin - Drug Profile 84
Anti-Pseudomonas IgY - Drug Profile 85
ceftobiprole medocaril - Drug Profile 87
gallium citrate - Drug Profile 90
tobramycin - Drug Profile 91
DasKloster-027401 - Drug Profile 92
SASPject PT3.1 - Drug Profile 93
SASPject PT3.X - Drug Profile 94
RX-P763 - Drug Profile 95
RX-P766 - Drug Profile 97
EV-035 - Drug Profile 99
tetracycline - Drug Profile 100
TP-433 - Drug Profile 101
RX-P792 - Drug Profile 102
RX-P793 - Drug Profile 104
RX-P808 - Drug Profile 105
RX-P770 - Drug Profile 106
Gram-Negative Programme - Drug Profile 108
Gram Negative Antibacterial Programs - Drug Profile 109
PopB-Based Vaccine - Drug Profile 110
PTX-005 - Drug Profile 111
Pseudomonas Program - Drug Profile 112
ACHN-978 - Drug Profile 113
Pseudovac Vaccine - Drug Profile 114
Snare Antibacterial For Gram Negative Infections - Drug Profile 115
(RPX2003 + RPX7009) - Drug Profile 116
NB-401 - Drug Profile 117
Immunoglobulin Y - Drug Profile 118
Pseudomonas Aeruginosa Vaccine - Drug Profile 119
Vaccine For Pseudomonas - Drug Profile 120
Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 121
SXP-2554 - Drug Profile 122
BioPhage-PR - Drug Profile 123
Type III Secretion System (T3SS) Inhibitors - Drug Profile 124
Pseudomonas Infections Therapeutics – Drug Profile Updates 125
Pseudomonas Infections Therapeutics – Discontinued Products 142
Pseudomonas Infections Therapeutics - Dormant Products 143
Pseudomonas Infections – Product Development Milestones 144
Featured News & Press Releases 144
Appendix 152
Methodology 152
Coverage 152
Secondary Research 152
Primary Research 152
Expert Panel Validation 152
Contact Us 153
Disclaimer 153

List of Tables
Number of Products Under Development for Pseudomonas Infections, H2 2012 13
Products under Development for Pseudomonas Infections – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Development by Companies, H2 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 19
Comparative Analysis by Late Stage Development, H2 2012 20
Comparative Analysis by Mid Clinical Stage Development, H2 2012 21
Comparative Analysis by Early Clinical Stage Development, H2 2012 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 23
Products under Development by Companies, H2 2012 24
Products under Development by Companies, H2 2012 (Contd..1) 25
Products under Development by Companies, H2 2012 (Contd..2) 26
Products under Development by Companies, H2 2012 (Contd..3) 27
Products under Investigation by Universities/Institutes, H2 2012 28
Aradigm Corporation, H2 2012 29
Sanofi-Aventis, H2 2012 30
Targeted Genetics Corporation, H2 2012 31
Merck & Co., Inc., H2 2012 32
Symphogen A/S, H2 2012 33
Rib-X Pharmaceuticals, Inc., H2 2012 34
Novartis AG, H2 2012 35
Bayer AG, H2 2012 36
PARI Pharma GmbH, H2 2012 37
Insmed Incorporated, H2 2012 38
Intercell AG, H2 2012 39
Basilea Pharmaceutica Ltd., H2 2012 40
Achaogen Inc., H2 2012 41
Evolva SA, H2 2012 42
Novexel SA, H2 2012 43
Aridis Pharmaceuticals LLC, H2 2012 44
Mondobiotech Holding AG, H2 2012 45
Kenta Biotech Ltd., H2 2012 46
Polyphor Ltd., H2 2012 47
Microbiotix, Inc., H2 2012 48
NanoBio Corporation, H2 2012 49
Ancora Pharmaceuticals Inc., H2 2012 50
Tetraphase Pharmaceuticals Inc., H2 2012 51
GlycoMimetics, Inc., H2 2012 52
Phico Therapeutics Ltd., H2 2012 53
SelectX Pharmaceuticals, Inc., H2 2012 54
PepTx, Inc., H2 2012 55
Trana Discovery, Inc., H2 2012 56
Cantab Biopharmaceuticals Limited, H2 2012 57
Assessment by Monotherapy Products, H2 2012 58
Assessment by Combination Products, H2 2012 59
Assessment by Stage and Route of Administration, H2 2012 61
Assessment by Stage and Molecule Type, H2 2012 63
Pseudomonas Infections Therapeutics – Drug Profile Updates 129
Pseudomonas Infections Therapeutics – Discontinued Products 146
Pseudomonas Infections Therapeutics – Dormant Products 147

List of Figures
Number of Products under Development for Pseudomonas Infections, H2 2012 13
Products under Development for Pseudomonas Infections – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 20
Mid Clinical Stage Products, H2 2012 21
Early Clinical Stage Products, H2 2012 22
Discovery and Pre-Clinical Stage Products, H2 2012 23
Assessment by Monotherapy Products, H2 2012 58
Assessment by Combination Products, H2 2012 59
Assessment by Route of Administration, H2 2012 60
Assessment by Stage and Route of Administration, H2 2012 61
Assessment by Molecule Type, H2 2012 62
Assessment by Stage and Molecule Type, H2 2012 63

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos